Additionally, BET inhibitors can modulate the immune microenvironment: GBM is immunosuppressive partly via expression of checkpoint ligands and cytokines, some of which are regulated by BRD4 (like IL-6, IL-8). This evidence concerns the gene BRD4 and glioblastoma.